Series of skin-whitening (lightening) compounds
US-11739040-B2 · Aug 29, 2023 · US
US12227472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12227472-B2 |
| Application number | US-202318238905-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 28, 2023 |
| Priority date | Jul 21, 2008 |
| Publication date | Feb 18, 2025 |
| Grant date | Feb 18, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising the compound of Formula V: or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from the group consisting of H or C 1 -C 10 alkyl; Bn is a benzyl; and R′ is 1 to 3 moieties (R′, R″, R′″) independently selected from the group consisting of a C 1 -C 10 alkyl group, a C 1 -C 10 alkoxy group or a hydroxyl group; and a pharmaceutically or cosmetically acceptable carrier. 2. A method of producing the compound in claim 1 by utilizing a compound comprising Formula IV as a starter compound or an intermediate compound: wherein represents double or single bond, R 1 is selected from the group consisting of H or C 1 -C 10 alkyl; R 4 is selected from the group consisting of H, OH or O; and R 5 is a selected from the group consisting of a substituted or unsubstituted: aromatic ring, heteroaromatic ring, heterocyclic ring or a hydroxylalkyl moiety. 3. The method of claim 2 , wherein R 1 is H or CH 3 and R 5 is selected from a substituted or unsubstituted: aromatic ring, heteroaromatic ring or a heterocyclic ring or a C 1 -C 10 hydroxylalkyl (—C 1 -C 10 )—OH). 4. The method of claim 2 , wherein R 5 is substituted with 1 to 3 moieties (R′, R″, R′″) independently selected from the group consisting of a C 1 -C 10 alkyl group, a C 1 -C 10 alkoxy group or a hydroxyl group.
Aryl or substituted aryl radicals · CPC title
attached in position 2 or 6 · CPC title
Anti-ageing preparations · CPC title
only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455) · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.